IP50: Bladder Cancer: Non-invasive IV
Sunday, May 17, 2026 7:00 AM to 9:00 AM · 2 hr. (America/New_York)
146A
Poster and Podium Sessions
Oncology: Bladder
Sunday, May 17
IP50-01: Comparative Effectiveness of Gemcitabine Intravesical System vs Real-World Intravesical Chemotherapy in BCG-Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer with Carcinoma in Situ: An Indirect Treatment Comparison Using an External Contr
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Girish Kulkarni · University of Toronto
IP50-02: Oncological benefits of a single immediate instillation of chemotherapy in patients with high-risk non-muscle-invasive bladder cancer who receive adjuvant induction bacillus Calmette-Guérin therapy
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Naoki Fujita · Hirosaki University Graduate School of Medicine
IP50-03: Evaluating CxMonitor as an alternative to flexible cystoscopy in bladder cancer surveillance: A multi-centre analysis of diagnostic performance, cost, and patient-reported outcomes
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Jeffery Yang · South West Sydney Local Health District
IP50-04: Early BCG Instillation Outweighs Second TURBT Timing for Recurrence-Free Survival in High-Risk NMIBC
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Zhenhua Liu
IP50-05: Using Artificial Intelligence to Distinguish Low Grade Urothelial Carcinoma from Benign Pathology on TURBT Surgical Video
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Abhinav Khanna · Mayo Clinic
IP50-06: Defining Unique Molecular Signatures of Young-Onset Non–Muscle-Invasive Bladder Cancer
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Joseph Black · Beth Israel Deaconess Medical Center
IP50-07: Defining the BCG-Exposed Phenotype in NMIBC: Stratified Outcomes and Treatment Pathways
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Renzo Di Natale · Virginia Mason Medical Center
IP50-08: FGFR3 Mutation with CDKN2A Deletion Defines an Aggressive Subtype with Poor Outcomes Across the Grade Spectrum of Non-Muscle Invasive Bladder Cancer (NMIBC)
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Mark Farha · New York Presbyterian - Weill Cornell
IP50-09: A Time Toxicity Analysis of BCG and Sequential Gemcitabine and Docetaxel for Non-Muscle-Invasive Bladder Cancer
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Melinda Fu · Rutgers RWJ
IP50-10: A Histopathology-Driven AI Biomarker for Predicting Progression, High-Grade Recurrence, and Early BCG Failure in NMIBC
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Kyle Richards · University of Wisconsin, Department of Urology, Division of Urologic Oncology
IP50-11: Comparative Outcomes of Gemcitabine Alone versus Gemcitabine + Docetaxel in Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Ao Zhang · Cleveland Clinic
IP50-12: An Indirect Treatment Comparison (ITC) of Nogapendekin Alfa Inbakicept-pmln plus Bacillus Calmette–Guérin (NAI+BCG) and TAR-200 in patients with BCG-unresponsive, Non-Muscle Invasive Bladder Cancer CIS ± Papillary (NMIBC).
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Scott Flanders · ImmunityBio, Inc.
IP50-13: Sequential instillation of intravesical docetaxel and gemcitabine in patients with non-muscle invasive bladder cancer
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Nancy Wei · Columbia University Medical Center
IP50-14: Does Second Look TURBT for High-Risk Non-Muscle Invasive Bladder Cancer Improve Response to Adjuvant Intravesical Therapy?
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Yakov Klugman · Roswell Park Comprehensive Cancer Center
IP50-15: Blue-light–Guided Transurethral Laser Ablation (TULA) for Non-Muscle-Invasive Bladder Cancer: First UK Single-Centre Experience on Recurrence-Free Survival
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Yasmin Abu-Ghanem
IP50-18: Drug-Releasing Intravesical Floating Technology (DRIFT) for Administration of Sequential Gemcitabine and Docetaxel in NMIBC
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Melinda Fu · Rutgers RWJ
IP50-19: Diuretic Effect Associated with Nadofaragene Firadenovec Instillation Therapy - Insight into Treatment Tolerability
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Abigail Keller · Fox Chase - Temple Urologic Institute
IP50-20: Sanctuary Site Evaluation in Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Gabriella Seo
IP50-21: A Real-World Case Series of Re-Induction With Nadofaragene Firadenovec in Patients With Carcinoma In Situ ± Papillary Non–Muscle-Invasive Bladder Cancer
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Chad Reichard · Urology of Indiana; US Urology Partners
IP50-22: Triglyceride-to-HDL Ratio Predicts Early Recurrence in Non-Muscle-Invasive Bladder Cancer: A 12- and 24-Month Survival Analysis
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Fernando Loyola Nieto · Universidad Panamericana School of Medicine
IP50-23: Active Surveillance in Low-Grade NMIBC: Results of an International Modified two-rounds Delphi Consensus
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
ROBERTO CONTIERI · Humanitas University
IP50-24: Clinical Outcomes of Nadofaragene Firadenovac in BCG Unresponsive NMIBC: A Multi-Center analysis
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Abhilash Moolupuri · University of Tennessee, Knoxville
IP50-26: Oncologic Outcomes of BCG Versus Observation in Patients with Intermediate-Risk NMIBC
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Simone D'Annunzio
IP50-27: Bladder EpiCheck as a tool for better risk stratification following inconclusive urinary cytology and negative cystoscopy
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Lourdes Mengual
IP50-28: Quality care measures among patients with high-risk non-muscle invasive bladder cancer with papillary carcinoma or carcinoma in situ receiving front-line Bacillus Calmette-Guérin or other intravesical therapies
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Mukul Singhal · Johnson and Johnson
IP50-29: Predictors of Severe Patient-Reported Toxicity During Intravesical Therapy for Non-Muscle Invasive Bladder Cancer
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Matthew Clements · Lahey Hospital & Medical Center
IP50-30: Contemporary analysis on patients with non-muscle invasive bladder cancer harboring CIS: results from 10-years of follow-up
Sunday, May 17, 2026 7:00 AM to 9:00 AM
146A
Giulio Avesani · Fundació Puigvert, Barcelona
